
A study involving 5,000 participants, demonstrated that a twice-yearly injection of lenacapavir offers total protection against HIV infection for young women, outperforming two daily PrEP pills: Truvada (F/TDF) and Descovy (F/TAF). Lenacapavir, a fusion capsid inhibitor, interferes with HIV's protein shell, preventing replication. The study, led by Gilead Sciences, aimed to establish lenacapavir's safety and efficacy compared to the established daily pills. This breakthrough highlights lenacapavir’s superior pharmacokinetic properties and its potential to enhance HIV prevention efforts significantly.
Like
Save
Share